Frovatriptan

Frovatriptan
Clinical data
Trade names	Frova
Other names	SB-209509; SB209509; EN-3266; EN3266; VML-251; VML251
AHFS/Drugs.com	Monograph
MedlinePlus	a604013
License data	US DailyMed: Frovatriptan;
Pregnancy; category	AU: B3;
Routes of; administration	Oral
Drug class	Serotonin 5-HT1B, 5-HT1D, 5-HT1F, and 5-HT7 receptor agonist
ATC code	N02CC07 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only;
Pharmacokinetic data
Bioavailability	20–30%
Metabolism	Liver
Elimination half-life	26–30 hours
Excretion	Kidney
Identifiers
	IUPAC name (+)-(R)-3-Methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole;
CAS Number	158747-02-5 ; succinate: 158930-17-7 ;
PubChem CID	77992;
IUPHAR/BPS	7191;
DrugBank	DB00998 ;
ChemSpider	70378 ;
UNII	H82Q2D5WA7; succinate: D28J6W18HY ;
KEGG	D07997 ;
ChEMBL	ChEMBL1279 ;
CompTox Dashboard (EPA)	DTXSID0023080 ;
Chemical and physical data
Formula	C14H17N3O
Molar mass	243.310 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN[C@@H]3CCc2[nH]c1ccc(C(N)=O)cc1c2C3;
	InChI InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1 ; Key:XPSQPHWEGNHMSK-SECBINFHSA-N ;
	(verify)

Frovatriptan, sold under the brand name Frova among others, is a triptan medication developed by Vernalis for the treatment of migraine headaches^[2] and for short term prevention of menstrual migraine.^[3]^[4] The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.^[5]

^ Cite error: The named reference Tfelt-HansenDeVriesSaxena2000 was invoked but never defined (see the help page).
^ Allais G, Benedetto C (2016). "Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine". Drug Design, Development and Therapy. 10: 3225–3236. doi:10.2147/DDDT.S105932. PMC 5055118. PMID 27757013.
^ MacGregor EA (2014). "A review of frovatriptan for the treatment of menstrual migraine". International Journal of Women's Health. 6: 523–35. doi:10.2147/IJWH.S63444. PMC 4039425. PMID 24904224.
^ Cole P, Rabasseda X (September 2002). "Frovatriptan: a selective type 1B/1D serotonin receptor agonist for the treatment of migraine headache". Drugs Today (Barc). 38 (9): 615–629. doi:10.1358/dot.2002.38.9.696537. PMID 12582449.
^ "Frova". Vernalis. Archived from the original on 27 September 2007. Retrieved 28 November 2007.

[Tfelt-HansenDeVriesSaxena2000-1] Cite error: The named reference Tfelt-HansenDeVriesSaxena2000 was invoked but never defined (see the help page).

[pmid27757013-2] Allais G, Benedetto C (2016). "Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine". Drug Design, Development and Therapy. 10: 3225–3236. doi:10.2147/DDDT.S105932. PMC 5055118. PMID 27757013.

[pmid24904224-3] MacGregor EA (2014). "A review of frovatriptan for the treatment of menstrual migraine". International Journal of Women's Health. 6: 523–35. doi:10.2147/IJWH.S63444. PMC 4039425. PMID 24904224.

[ColeRabasseda2002-4] Cole P, Rabasseda X (September 2002). "Frovatriptan: a selective type 1B/1D serotonin receptor agonist for the treatment of migraine headache". Drugs Today (Barc). 38 (9): 615–629. doi:10.1358/dot.2002.38.9.696537. PMID 12582449.

[5] "Frova". Vernalis. Archived from the original on 27 September 2007. Retrieved 28 November 2007.

[1]

[2]

[3]

[4]

[5]